NantHealth Revenue, Valuation, Funding & Investors
NantHealth is valued at $2B as of June 2015.
Last NantHealth valuation
$2B
Undisclosed stage · Jun 2015
Last NantHealth funding round
$53M
Undisclosed stage · Jan 2016
NantHealth revenue
$58M
Undisclosed stage · Nov 2014
Key investors in NantHealth
Celgene
Blackstone
Veradigm
BlackBerry
Kuwait Investment Authority
About NantHealth
NantHealth is a Culver City, California-headquartered precision medicine company that delivers genomic sequencing and molecular diagnostics through its Navify platform for oncology and rare diseases. The firm integrates multi-omic data to guide personalized treatment decisions in partnerships with hospitals across the United States.
Founded
2007
HQ
Los Angeles, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Revenue
$58M (Nov 2014)
Valuation
$2B (Jun 2015)
NantHealth Valuation
NantHealth is currently valued at $2B, based on its undisclosed-stage round in June 2015.
The $200M round was led by Veradigm.
NantHealth's valuation has grown 8.0x from $250M at its undisclosed-stage round in November 2014 to $2B in June 2015, across 2 priced rounds.
NantHealth valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Jun 2015 | Undisclosed stage | $2B | - |
| Nov 2014 | Undisclosed stage | $250M | 4.3x |
NantHealth Revenue
NantHealth's latest recorded revenue is $58M, as of its undisclosed-stage round in November 2014. At a $250M valuation, that implies a 4.3x revenue multiple.
NantHealth revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Nov 2014 | $58M | $250M | 4.3x | Undisclosed stage |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
NantHealth Funding History
NantHealth has raised a total of $708M across 7 funding rounds.
NantHealth's first fundraising round was a $25M Series B in September 2013. The most recent completed round was a $53M undisclosed-stage round in January 2016.
NantHealth funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2016 | Undisclosed stage | - | $53M | - | NantHealth is a precision medicine and healthcare IT company offering platforms like NantOS, NaviNet, and GPS Cancer for clinical decision support, connected care, and molecular diagnostics. It reported full-year 2016 total net revenue of $100 million, a 72% increase from $58 million in 2015, with SaaS-based revenue growing over 181%. The company sold over 25,000 Device Connect licenses integrated with 18 EMRs across 300 provider sites and increased NantOS/NaviNet commitments from 35 to 96 in Q4 2016. Prior to its June 2016 IPO, NantHealth raised $160 million in a growth round on February 6, 2015, and earlier $320 million Series B on June 18, 2014, and $25 million venture round on June 5, 2014, to fund innovation in patient care, cancer research, and healthcare transformation. The IPO priced at around $14-19 per share, creating nearly $1.5 billion market cap, with an EV/Revenue multiple of 17.2x based on 2016 revenue. Financials for 2016 showed SG&A expenses of $120.7 million (up from $69 million prior year), R&D at $61.6 million (from $23.8 million), and a net loss of $184.1 million including $41 million loss from related party investment and $29.8 million impairment in NantOmics due to delayed GPS test sales. Balance sheet included goodwill of $131 million and intangible assets of $119 million as of year-end. NantHealth ranked #1 in clinical decision support by Black Book research at 2016 HIMSS and targeted the $250 billion precision medicine market. It pursued CMS coverage for GPS Cancer and had over 60% of U.S. physicians' offices as potential reach. Post-IPO trading was below listing price, aligning with slower public market activity for digital health in 2016. |
| Jun 2015 | Undisclosed stage | Veradigm (lead) | $200M | $2B | NantHealth, a healthcare IT company focused on precision medicine and connected care solutions, raised $200 million in new funding in 2015, bringing its total funding to $680 million as part of the year's digital health investment surge. This round occurred amid a year where venture capital deals in digital health topped $4.3 billion, with NantHealth's investment highlighting investments in more mature companies. The funding came during a period of active M&A in digital health, with the Allscripts-NantHealth deal noted as one of the largest, though specifics distinguish it from the $200M VC raise. Later interactions between the companies included Allscripts acquiring NantHealth's patient-engagement assets in 2017. NantHealth's broader ecosystem involved partnerships and integrations in health IT, aligning with Veradigm's (Allscripts') acquisitions like CHMB Inc. in 2015 to expand billing and systems capabilities. |
| May 2015 | Series A | - | $10M | - | NantHealth raised $160 million in a growth round on February 6, 2015. The company also secured $200 million in new funding from Allscripts in 2015, bringing total funding to date to $680 million. Prior rounds included a $320 million Series B on June 18, 2014, and a $25 million venture round on June 5, 2014. |
| Nov 2014 | Undisclosed stage | - | $25M | $250M | NantHealth, a cloud-based clinical operating software provider focused on digital health solutions, received significant investments around mid-2014. In May 2014, it secured a $100 million investment from a sovereign wealth fund, identified as the Kuwait Investment Authority. This was followed by a $25 million corporate minority investment from Celgene in June 2014. Earlier in April 2014, NantHealth raised about $135 million from the Kuwait Investment Authority and an undisclosed amount from BlackBerry. A McGuireWoods venture capital report from December 2014 highlights NantHealth as a well-funded Los Angeles company that recently completed a $250 million Series B equity round, positioning it among top-funded firms in the region amid a surge in digital health investments totaling $2.2 billion in the first half of 2014. Other investors included Verizon with an undisclosed amount for developing secure cloud-based healthcare data infrastructure. Cumulative funding reached $166 million by mid-2014 according to some reports. |
| May 2014 | Series B | BlackBerry (lead); Blackstone (lead); Kuwait Investment Authority (lead) | $320M | - | NantHealth, a NantWorks company focused on transforming healthcare through science, data, and technology, completed a $320 million Series B equity investment announced on October 1, 2014. The round included $250 million from the Kuwait Investment Authority (KIA), a major sovereign wealth fund, building on prior funding and strategic participation from BlackBerry, Blackstone, Verizon, and Celgene. This investment aimed to accelerate innovation in personalized medicine, real-time data sharing, and cost reduction in healthcare delivery. The company's core offering is the NantHealth Clinical Operating System (cOS), a platform that integrates molecular science, near real-time patient signal monitoring from medical devices, computer science, and big data analytics. It enables physicians, patients, payers, and researchers to access actionable clinical intelligence, collaborate in real-time, analyze genomic signatures, and improve treatment decisions and outcomes. Earlier reports noted the platform installed in approximately 260 hospitals, connecting over 16,000 devices and collecting more than 3 billion vital signs annually, though these metrics predate the full round close. NantHealth expanded its leadership team with healthcare industry veterans to drive commercialization and execution of its vision for value-based population healthcare and 21st-century genomically informed care. Strategic partnerships, such as with BlackBerry for a healthcare-specific smartphone launch targeted for late 2014 or early 2015, underscored efforts to enhance secure data sharing and compliance in the industry. The funding positioned NantHealth for global scale, emphasizing a 'Global Healthcare Cooperative' model to share breakthrough medicines and information worldwide. |
| Jan 2014 | Undisclosed stage | Celgene | $75M | - | NantHealth, founded by Dr. Patrick Soon-Shiong, develops precision medicine solutions including the Comprehensive Learning Integrated NantHealth Intelligent Clinical System (CLINICS), which integrates systems infrastructure, knowledge platforms, provider platforms, and payor platforms for molecularly precise care. The company provides software solutions, SaaS, hardware, services, and GPS Cancer tests to healthcare providers, payors, and employers, targeting a global market exceeding $50 billion. In early 2014, Celgene invested $25 million in NantHealth as part of strategic collaborations to advance cancer research, detection, prevention, diagnosis, and treatment using NantHealth's clinical operating system and genomic analysis capabilities. This followed Celgene's $75 million investment earlier that year in NantBioScience, another NantWorks company. Later in 2014, NantHealth raised a larger round totaling $320 million, including $250 million from Kuwait Investment Authority, with participation from Celgene, Verizon, and BlackBerry. Additionally, Allscripts invested $200 million about a year before the IPO filing. For the year ended December 31, 2015, NantHealth reported total net revenue of $58.3 million, primarily from licensed software, maintenance, SaaS, hardware, services, and GPS Cancer, with some from drug development services and genomics/proteomics analysis. The company posted a net loss of $72 million that year. On a pro forma basis including equity investment in NantOmics and acquisition of NaviNet, revenue rose to $112.9 million with a net loss of $97.7 million. NantHealth went public in 2016, raising $91 million in its IPO, supported heavily by existing investors like Celgene and Soon-Shiong entities. |
| Sep 2013 | Series B | Celgene (lead) | $25M | - | NantHealth, founded in 2007 and part of the NantWorks ecosystem led by Dr. Patrick Soon-Shiong, develops clinical decision support systems including the clinical operating system (cOS), genomic analysis tools, and a cancer clinical trials search engine to aid in personalized cancer detection, diagnosis, and treatment. In June 2013, Celgene invested $25 million in NantHealth, described as a landmark strategic investment to advance groundbreaking cancer research and leverage NantHealth's knowledge base for molecular-designed treatments. This followed Celgene's earlier $75 million investment in NantBioScience, another NantWorks company, earlier in 2013. The $25 million Celgene round was part of broader funding for NantHealth, which had raised $166 million total by mid-2014 including $100 million from Kuwait Investment Authority, undisclosed amounts from BlackBerry and Verizon, and a later $320 million round led by KIA with participation from Celgene, Verizon, and BlackBerry. The investment aimed to empower clinicians with real-time supercomputing and molecular analysis at the point of care. NantHealth emerged from stealth with innovative healthcare IT solutions, positioning against traditional systems by integrating genomic data and cloud infrastructure for mobile delivery of patient information. |
Who has invested in NantHealth?
5 investors have backed NantHealth across its funding rounds, including Celgene, Blackstone, Veradigm, BlackBerry and Kuwait Investment Authority.
Lead investors include Veradigm, BlackBerry, Blackstone, Kuwait Investment Authority and Celgene.
NantHealth Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Summit, NJ | 2 | Lead | Sep 2013 | |
 Kuwait City | 1 | Lead | May 2014 | |
| New York City, NY | 1 | Lead | May 2014 | |
This data is available for Pro users. Sign up to see all 5 NantHealth investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by NantHealth
NantHealth has acquired 8 companies to date.
Last acquisition by NantHealth was on July 27th 2020. NantHealth acquired The OpenNMS Group for undisclosed valuation.
Latest Acquisitions by NantHealth
| Description | The OpenNMS Group is a Cedar Rapids-headquartered provider of the OpenNMS open-source network monitoring platform used by enterprises in healthcare, finance, and government sectors. It tracks tens of thousands of devices with fault detection, performance metrics, and flow analysis integrating with tools like Grafana and Elasticsearch. Founded in 1999, OpenNMS Horizon and Meridian editions support distributed deployments worldwide. | NaviNet provides healthcare communications solutions from its base in Cambridge, Massachusetts, where it was founded in 1997 and renamed from NaviMedix in 2009. The platform includes Insurer Connect for insurance plan access, Payment Management for fund collection, Patient Care Connect for collaboration among patients, insurers, providers, and partners, plus Office Efficiency tools for workflow streamlining. Services cover claim management, authorizations, clinical messaging, health record exchange, and provider network communications for health plans across the United States. | Health Heritage is a Boston-based digital health company offering a platform that analyzes electronic medical records to assess hereditary disease risks like breast cancer and type 2 diabetes. The tool extracts family medical history, facilitates secure sharing among relatives, and generates personalized screening recommendations validated by guidelines from the National Comprehensive Cancer Network. Health Heritage partners with health systems including Mass General Brigham and has analyzed records for over 50,000 users since its 2015 launch. Its algorithms incorporate genetic data from sources like 23andMe to refine risk profiles and suggest preventive measures. | iSirona is a provider of medical device integration software connecting devices to clinical information systems. The Alpharetta, Georgia-headquartered company enables real-time data flow from monitors, ventilators, and infusion pumps into EHRs like Epic and Cerner. Its solutions support waveform viewing, alarm management, and analytics for hospitals seeking improved clinician workflows and decision-making. | |
| HQ Country | | | | | |
| HQ City | Raleigh, NC | Boston, MA | Chicago, IL | - | |
| Deal Date | 27 Jul 2020 | 1 Jan 2016 | 26 Oct 2015 | 26 Oct 2015 | |
| Valuation | undisclosed | $151M | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all NantHealth acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by NantHealth
NantHealth has invested in 2 companies to date.
Latest investment by NantHealth was on June 1st 2015. NantHealth invested in NantOmics in their $251M Series A round.
Latest Investments by NantHealth
| Description | NantOmics is a Culver City-headquartered molecular diagnostics company that develops cloud-based molecular profiling tools, including the GPS Cancer test and OncoPlexDx Targeted Proteomic panel, to guide personalized cancer treatments for patients and oncologists. As a subsidiary of NantWorks, it delivers point-of-care insights into cancer biology through quantitative protein biomarkers and genomic profiles. NantOmics supports treatment strategies in clinical settings across the United States, with headquarters in California and integration into broader precision medicine platforms. | Fluential is an advanced speech technology company developing linguistic interfaces for military, healthcare, and consumer applications. Its multimodal voice systems integrate with mobile devices for hands-free interactions in secure environments. |
| HQ Country | | |
| HQ City | Los Angeles, CA | San Francisco, CA |
| Deal Date | 1 Jun 2015 | 21 Nov 2013 |
| Round | Series A | Angel |
| Raised | $251M | $8M |
| Investors | - | - |
| Valuation | $1.7B | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all NantHealth investments and their VC round multiples. Start Free Trial | ||
NantHealth Competitors
NantHealth competitors include listed companies like Privia Health, Indegene and Veradigm, and private ones like Unite Us, Innovaccer and Truveta.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| New York City, NY | Private | - | - | $1.6B | - | |
| United States | Publicly listed | $2.1B | $44M | $2.6B | 0.9x | |
 India | Publicly listed | $366M | $68M | $1.5B | 3.3x | |
| San Francisco, CA | Private | $250M | - | $3.5B | 13.8x | |
| Seattle, WA | Private | - | - | $1B | - | |
| United States | Publicly listed | $588M | $54M | $523M | 0.9x |
NantHealth Public Comps
NantHealth is still privately-owned, but its public comps include Qingdao Baheal Medical, Schrödinger, Dian Diagnostics Group, Clover Health, Tieto, JMDC, Omnicell, Indegene, Nutex Health and Privia Health.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.1B | $139M | 1.9x | 1.9x | 15.1x | 16.8x | |||
| $256M | ($96M) | 7.6x | 7.9x | (20.3x) | (14.0x) | |||
| $1.5B | $127M | 1.4x | 1.4x | 16.4x | 12.2x | |||
| $1.9B | ($84M) | 1.1x | 0.8x | (25.8x) | 34.1x | |||
| $2.1B | $186M | 1.3x | 1.4x | 15.2x | 7.9x | |||
| $324M | $88M | 5.0x | 4.6x | 18.4x | 17.9x | |||
| $1.2B | $92M | 1.2x | 1.1x | 15.0x | 8.1x | |||
| $366M | $68M | 3.7x | 3.3x | 19.9x | 18.2x | |||
This data is available for Pro users. Sign up to see all NantHealth competitors and their valuation data. Start Free Trial | ||||||||
Common questions about NantHealth
| When was NantHealth founded? | NantHealth was founded in 2007. |
| Where is NantHealth headquartered? | NantHealth is headquartered in Los Angeles, CA, United States. |
| Is NantHealth publicly listed? | No, NantHealth is a private, VC-backed company. |
| What is NantHealth's valuation? | NantHealth was last valued at $2B in its undisclosed-stage round in June 2015. |
| How much funding has NantHealth raised? | NantHealth has raised $708M across 7 funding rounds. |
| What was NantHealth's last funding round? | NantHealth's last funding round was a $53M undisclosed-stage round in January 2016. |
| Who are NantHealth's investors? | NantHealth's investors include Celgene, Kuwait Investment Authority, Blackstone, BlackBerry and Veradigm. |
| What is NantHealth's revenue? | NantHealth's latest recorded revenue is $58M (November 2014). |
| What is NantHealth's revenue multiple? | NantHealth's latest valuation implies a 4.3x revenue multiple ($250M valuation on $58M of revenue). |
| Which companies are comparable to NantHealth? | Companies comparable to NantHealth include Unite Us, Privia Health, Indegene, Innovaccer, Truveta and Veradigm. |
| How many companies has NantHealth acquired? | NantHealth has acquired 8 companies, including The OpenNMS Group, NaviNet, Health Heritage, iSirona and Harris Healthcare Solutions. |
| What was the largest acquisition by NantHealth? | The $151M acquisition of NaviNet in January 2016 is the largest acquisition NantHealth has made to date. |
| How many companies has NantHealth invested in? | NantHealth has invested in 2 companies, including NantOmics and Fluential. |
| What was NantHealth's last investment? | In June 2015, NantHealth invested in NantOmics' $251M Series A. |
See companies similar to NantHealth
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.